Impact Biomedical (IBO) Revenue (2022 - 2026)

Impact Biomedical's (IBO) quarterly Revenue came in at $7000.0 in Q1 2026, down 61.11% on a QoQ basis from $18000.0 in Q3 2025.

Impact Biomedical (IBO) Revenue (2022 - 2026) Analysis & Trends

Impact Biomedical (IBO) has 3 years of Revenue data on file, last reported at $7000.0 in Q1 2026.

Quarterly Revenue changed N/A year-over-year to $7000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32000.0 (changed N/A YoY) and the FY2022 annual result came in at $50000.0, changed N/A from the prior year.
Revenue fell to $7000.0 in Q1 2026, from $18000.0 in the prior quarter.
In the past five years, Revenue ranged from a high of $50000.0 in Q2 2022 to a low of $7000.0 in Q2 2025.
A 3-year average of $20500.0 and a median of $12500.0 in 2025 frame the typical range for Revenue.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Vertex Pharmaceuticals	138.04 Bn	130.18 Bn	2.84 Bn	3.33 Bn
2	Regeneron Pharmaceuticals	85.98 Bn	77.98 Bn	3.93 Bn	4.29 Bn
3	Argenx Se	64.37 Bn	59.19 Bn	1.37 Bn	1.52 Bn
4	Moderna	57.67 Bn	52.53 Bn	52.00 Mn	145.00 Mn
5	BeOne Medicines	41.94 Bn	36.84 Bn	1.53 Bn	1.71 Bn
6	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	1.29 Bn
7	BioNTech SE	27.75 Bn	9.35 Bn	668.28 Mn	1.06 Bn
8	Insmed	27.24 Bn	26.08 Bn	358.27 Mn	425.49 Mn
9	Royalty Pharma	27.03 Bn	26.20 Bn	-	674.14 Mn
10	Impact Biomedical	47.26 Mn	47.25 Mn	2,000.00	3,000.00

Download Data